DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the stock.

A number of other research firms also recently weighed in on DBVT. HC Wainwright reissued a buy rating and set a $5.00 price target on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities reaffirmed a market outperform rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Price Performance

DBVT opened at $0.70 on Friday. The company has a market cap of $67.55 million, a price-to-earnings ratio of -0.83 and a beta of 0.67. The firm has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $0.99. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.40.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the firm earned ($0.26) earnings per share. As a group, analysts expect that DBV Technologies will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.